and power can be misused (Montgomery and power can be misused (Montgomery et al et al, 2004; Heres , 2004; Heres et al et al, 2006) ; nevertheless, , 2006); nevertheless, industry invests more in research and industry invests more in research and development than all 'independent' sources, development than all 'independent' sources, and this is likely to remain the case. and this is likely to remain the case.
Relentless industry marketingRelentless industry marketingwhether in the form of advertisements, whether in the form of advertisements, research articles, teaching events, opinion research articles, teaching events, opinion leader talks, guideline lobbying, media leader talks, guideline lobbying, media seeding, visiting sales representatives or seeding, visiting sales representatives or even that not-so-free pizza (Moynihan, even that not-so-free pizza (Moynihan, 2003 2003a a, ,b b) -fosters hope of the new being ) -fosters hope of the new being better than the old. For about two decades better than the old. For about two decades after their patenting, new drug treatments after their patenting, new drug treatments are expensive. Even in countries where genare expensive. Even in countries where generic manufacturing of new drugs occurs eric manufacturing of new drugs occurs through the legal loophole of the 'process through the legal loophole of the 'process patent' -where it is only the process of patent' -where it is only the process of manufacture that is recognised as patented, manufacture that is recognised as patented, allowing the manufacture of a patented allowing the manufacture of a patented drug by altering the process even in a minor drug by altering the process even in a minor way -distribution may not be wide and the way -distribution may not be wide and the drugs can remain inaccessible. For example, drugs can remain inaccessible. For example, owing to loopholes in current patent law, owing to loopholes in current patent law, more than 20 brands of olanzapine and more than 20 brands of olanzapine and risperidone are available in India at a fracrisperidone are available in India at a fraction of 'Western' prices. In Bihar, one poor tion of 'Western' prices. In Bihar, one poor state in India, there are more people with state in India, there are more people with schizophrenia than in the whole of North schizophrenia than in the whole of North America. Nevertheless, even these cheaper America. Nevertheless, even these cheaper preparations are not affordable for the poor preparations are not affordable for the poor in Bihar and distribution through the state in Bihar and distribution through the state healthcare system is variable. In any case healthcare system is variable. In any case the World Trade Organisation and the the World Trade Organisation and the General Agreement on Tariffs and Trade General Agreement on Tariffs and Trade are ensuring that this loophole is being are ensuring that this loophole is being closed and countries are less readily able closed and countries are less readily able to exploit the current situation. In Brazil, to exploit the current situation. In Brazil, for example, atypical antipsychotic drugs for example, atypical antipsychotic drugs remain expensive and are only generally remain expensive and are only generally affordable if paid for by the state, and this affordable if paid for by the state, and this provision varies. Four-fifths of the world's provision varies. Four-fifths of the world's population of people with schizophrenia population of people with schizophrenia live in low-or middle-income countries; live in low-or middle-income countries; nevertheless, global marketing relentlessly nevertheless, global marketing relentlessly promotes a collective guilt whereby to promotes a collective guilt whereby to advise the use of older, inexpensive drugs advise the use of older, inexpensive drugs is, somehow, to give a second-class service. is, somehow, to give a second-class service.
COMMERCIAL INTERESTS COMMERCIAL INTERESTS AND CLINICAL EVIDENCE AND CLINICAL EVIDENCE
It is hard to know the 'objective' facts It is hard to know the 'objective' facts about the effects of these treatments, and about the effects of these treatments, and it may be impossible during the period in it may be impossible during the period in which large pecuniary interests are heavily which large pecuniary interests are heavily involved. As time passes, more complete involved. As time passes, more complete data from known trials begin to emerge data from known trials begin to emerge and less-positive studies that had been and less-positive studies that had been previously unknown come to light previously unknown come to light (Easterbrook (Easterbrook et al et al, 1991; Gilbody , 1991; Gilbody et al et al, , 2000) . In addition, once a drug is off 2000). In addition, once a drug is off patent, companies may well be more generpatent, companies may well be more generous with data. Whether or not this is ous with data. Whether or not this is as it should be, it seems likely that as it should be, it seems likely that this situation will change only slowly this situation will change only slowly (Chalmers, 2006) . (Chalmers, 2006) .
Rich countries develop and evaluate the Rich countries develop and evaluate the new drugs, and these same nations are the new drugs, and these same nations are the first focus of the initial decades of marketfirst focus of the initial decades of marketing. As the battle of the companies is fought ing. As the battle of the companies is fought out in high-income countries, clouds of dust out in high-income countries, clouds of dust from marketing obscure the view. Unless from marketing obscure the view. Unless effects are dramatic, it takes decades for effects are dramatic, it takes decades for the dust to settle. For example, in the past the dust to settle. For example, in the past 20 years millions of people with schizo-20 years millions of people with schizophrenia in these high-income countries have phrenia in these high-income countries have been caught up in the struggle between been caught up in the struggle between companies producing different new anticompanies producing different new antipsychotic drugs. Inevitably there are psychotic drugs. Inevitably there are winners and losers. Many win. Everyone winners and losers. Many win. Everyone has been forced to be more thoughtful has been forced to be more thoughtful about prescribing, and new compounds about prescribing, and new compounds have their own effect profiles and are have their own effect profiles and are welcome additions to the management of welcome additions to the management of this difficult and damaging illness. On the this difficult and damaging illness. On the other hand, some in the rich nations suffer other hand, some in the rich nations suffer as a result of ill-publicised effects of the as a result of ill-publicised effects of the new drugs, and have to be compensated new drugs, and have to be compensated (McGough & Abboud, 2005) . However, (McGough & Abboud, 2005) . However, many more are not remunerated for the many more are not remunerated for the major or minor ill effects they suffer, save major or minor ill effects they suffer, save only in the knowledge that evidence of the only in the knowledge that evidence of the problems they encountered may be problems they encountered may be commonly known by the time the medicacommonly known by the time the medications become available to the other 80% tions become available to the other 80% of the world's population. of the world's population.
During this period many in the lowerDuring this period many in the lowerincome countries have to observe the battle income countries have to observe the battle from afar and they are forced to use older from afar and they are forced to use older drugs. On the other hand, much is known drugs. On the other hand, much is known about these familiar compounds. The about these familiar compounds. The battles that did rage for the firstbattles that did rage for the first-generation generation drugs are long over, and much positive and drugs are long over, and much positive and negative data are available. As time passes negative data are available. As time passes and and newer medication is becoming accessible newer medication is becoming accessible in less-affluent nations, the second generin less-affluent nations, the second generation of battles have lost some of their ation of battles have lost some of their urgency and aggression. urgency and aggression.
Here is the schizophrenia drug treatment Here is the schizophrenia drug treatment paradox. Evidence-based practice is the paradox. Evidence-based practice is the judicious use of the best available evidence judicious use of the best available evidence in patient care or policy making (Sackett in patient care or policy making (Sackett et et al al, 1997) . Judicious use of best available , 1997). Judicious use of best available evidence for the care of people with schizoevidence for the care of people with schizophrenia is possible everywhere. However, phrenia is possible everywhere. However, by the time drugs are widely accessible in by the time drugs are widely accessible in lower-income nations the 'best available lower-income nations the 'best available evidence' may well be better in these poor evidence' may well be better in these poor countries than was the case when the drugs countries than was the case when the drugs were first marketed in rich nations. were first marketed in rich nations.
Recent findings from larger pragmatic Recent findings from larger pragmatic and independently funded studies reinforce and independently funded studies reinforce this argument (Lieberman this argument (Lieberman et al et al, 2005; , 2005; Lewis Lewis et al et al, 2006) . If new drugs are com-, 2006). If new drugs are compared with haloperidol, an antipsychotic pared with haloperidol, an antipsychotic particularly associated with obvious particularly associated with obvious adverse effects, the new experimental adverse effects, the new experimental compound can hardly fail to seem beneficompound can hardly fail to seem beneficial in terms of adverse effects (Joy cial in terms of adverse effects (Joy et al et al, , 2001 ). If, however, newer compounds are 2001). If, however, newer compounds are compared with more benign older drugs compared with more benign older drugs there is a consistent finding that there is there is a consistent finding that there is little to choose between old and new medilittle to choose between old and new medications, even on adverse effect outcomes. cations, even on adverse effect outcomes. So shocking are these results to a subSo shocking are these results to a subspecialty convinced by marketing that the specialty convinced by marketing that the trialists themselves are surprised and pertrialists themselves are surprised and perplexed at the messages to give, and journals plexed at the messages to give, and journals may fail to encourage publication of may fail to encourage publication of important results. important results.
In both rich and poor countries, there is In both rich and poor countries, there is no need for collective guilt about use of no need for collective guilt about use of older treatments. Use of these tried and older treatments. Use of these tried and tested drugs has more chance of being tested drugs has more chance of being based on really good evidence than that of based on really good evidence than that of newcomers for which marketing interests newcomers for which marketing interests obfuscate fact. There is, however, an obfuscate fact. There is, however, an enormous need for more independent, enormous need for more independent, well-designed, conducted and reported well-designed, conducted and reported pragmatic randomised trials in this area. pragmatic randomised trials in this area. In order to offer people in rich countries In order to offer people in rich countries more protection from being unofficial more protection from being unofficial participants in enormous post-licensing participants in enormous post-licensing studies, these pragmatic randomised trials studies, these pragmatic randomised trials should take place before widespread should take place before widespread introduction of the drugs. introduction of the drugs.
